252 related articles for article (PubMed ID: 24505236)
1. Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation.
Schmitt M; Publicover A; Orchard KH; Görlach M; Wang L; Schmitt A; Mani J; Tsirigotis P; Kuriakose R; Nagler A
Theranostics; 2014; 4(3):280-9. PubMed ID: 24505236
[TBL] [Abstract][Full Text] [Related]
2. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF.
Schmitt M; Hoffmann JM; Lorenz K; Publicover A; Schmitt A; Nagler A
Vox Sang; 2016 Aug; 111(2):178-86. PubMed ID: 27509033
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience.
Islami MM; Khan MA; Aseeri MA; Alshamrani MA; Alnatsheh A; Alamoudi S; Alzahrani AA
Ann Transplant; 2023 Mar; 28():e938585. PubMed ID: 36864713
[TBL] [Abstract][Full Text] [Related]
6. Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption.
Aggarwal V; Sabry W; Elemary M; Bosch M; Danyluk P; Mondal P; Stakiw J
Curr Oncol; 2021 Apr; 28(3):1571-1580. PubMed ID: 33922026
[TBL] [Abstract][Full Text] [Related]
7. A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization.
Manko J; Walter-Croneck A; Jawniak D; Grzasko N; Gorska-Kosicka M; Cioch M; Dmoszynska A
Pharmacol Rep; 2014 Apr; 66(2):239-42. PubMed ID: 24911076
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.
Reményi P; Gopcsa L; Marton I; Réti M; Mikala G; Pető M; Barta A; Bátai A; Farkas Z; Borbényi Z; Csukly Z; Bodó I; Fábián J; Király A; Lengyel L; Piukovics K; Torbágyi E; Masszi T
Adv Ther; 2014 Apr; 31(4):451-60. PubMed ID: 24687301
[TBL] [Abstract][Full Text] [Related]
9. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
[TBL] [Abstract][Full Text] [Related]
10. Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors.
Schmitt M; Xu X; Hilgendorf I; Schneider C; Borchert K; Gläser D; Freund M; Schmitt A
Bone Marrow Transplant; 2013 Jul; 48(7):922-5. PubMed ID: 23318540
[TBL] [Abstract][Full Text] [Related]
11. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
[TBL] [Abstract][Full Text] [Related]
13. The comparison of effectiveness and safety between different biosimilars of G-CSF in the mobilization of peripheral blood stem cells (PBSCs) for autologous transplantation (autologous peripheral blood stem cell transplantation, auto-PBSCT).
Wicherska-Pawłowska K; Rybka J; Prajs I; Szmigiel K; Tyc J; Frączak E; Biedroń M; Kalicińska E; Szymczak D; Wróbel T
J Clin Apher; 2020 Jan; 35(1):4-8. PubMed ID: 31663634
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.
Cesaro S; Tridello G; Prete A; Dallorso S; Cannata E; Massaccesi E; Risso M; De Bortoli M; Caselli D
Transfusion; 2015 Feb; 55(2):246-52. PubMed ID: 25070657
[TBL] [Abstract][Full Text] [Related]
15. What is the role of biosimilar G-CSF agents in hematopoietic stem cell mobilization at present?
Korkmaz S; Altuntas F
Transfus Apher Sci; 2017 Dec; 56(6):795-799. PubMed ID: 29153313
[TBL] [Abstract][Full Text] [Related]
16. Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G-CSF (Zarzio®).
Antelo ML; Zabalza A; Sánchez Antón MP; Zalba S; Aznar M; Mansilla C; Ramírez N; Olavarría E
J Clin Apher; 2016 Feb; 31(1):48-52. PubMed ID: 26011178
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?
Bonig H; Becker PS; Schwebig A; Turner M
Transfusion; 2015 Feb; 55(2):430-9. PubMed ID: 24965197
[TBL] [Abstract][Full Text] [Related]
18. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421
[TBL] [Abstract][Full Text] [Related]
19. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
[TBL] [Abstract][Full Text] [Related]
20. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery.
Marchesi F; Mengarelli A
Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
